SCHEMBL1948735

SCHEMBL1948735

Cc1cccc(C)c1/N=C/c1ccccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.58
ALDH1A1 P00352 5/20 0.58
KDM4E B2RXH2 4/20 0.58
POLB P06746 2/20 0.58
MPI P34949 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
RECQL P46063 1/20 0.58
CA12 O43570 6/20 0.58
CA2 P00918 6/20 0.58
CA9 Q16790 5/20 0.58
SIRT2 Q8IXJ6 1/20 0.58
ALOX15 P16050 3/20 0.51
KMT2A Q03164 3/20 0.51
THRB P10828 2/20 0.51
PKM P14618 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1948736 1.00 MAPT (0.58) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL13779331 0.95 MAPT (0.57) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL1949778 0.86 SIRT2 (0.59) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL11182613 0.86 SIRT2 (0.59) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL11182598 0.86 SIRT2 (0.59) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL1949779 0.86 SIRT2 (0.59) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL11263405 0.84 CA12 (0.53) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL11263401 0.84 CA12 (0.53) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL12715038 0.84 ALDH1A1 (0.49) MAPTALDH1A1KDM4EPOLBMPI
SCHEMBL1950957 0.83 SIRT2 (0.56) MAPTALDH1A1KDM4EPOLBMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10160828-B2 Group 8 transition metal catalysts and method for making same and process for use of same in metathesis reaction GUANG MING INNOVATION COMPANY (WUHAN) (CN) 2018-12-25 US disclosed
US-9802972-B2 Ruthenium- or osmium-based complex catalysts ARLANXEO DEUTSCHLAND GMBH (DE) 2017-10-31 US disclosed
US-9802972-B2 Ruthenium- or osmium-based complex catalysts ARLANXEO DEUTSCHLAND GMBH (DE) 2017-10-31 US disclosed
US-20170145152-A1 GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION GUANG MING INNOVATION COMPANY (WUHAN) (CN) 2017-05-25 US disclosed
EP-3164409-A1 GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION Guang Ming Innovation Company (Wuhan) (CN) 2017-05-10 EP disclosed
US-20160122376-A1 RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS ARLANXEO DEUTSCHLAND GMBH (DE) 2016-05-05 US disclosed
US-20160122376-A1 RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS ARLANXEO DEUTSCHLAND GMBH (DE) 2016-05-05 US disclosed
EP-2151446-B1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand RIMTEC CORP (JP) 2016-04-13 EP disclosed
WO-2016000242-A1 GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION GUANG MING INNOVATION COMPANY (WUHAN) (CN) 2016-01-07 WO disclosed
WO-2016000242-A1 GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION GUANG MING INNOVATION COMPANY (WUHAN) (CN) 2016-01-07 WO disclosed
EP-2151445-B1 Process for the preparation of bidentate Schiff base ruthenium catalysts containing a salicylaldimine-type ligand RIMTEC CORP (JP) 2015-02-18 EP disclosed
WO-2014198022-A1 RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS LANXESS DEUTSCHLAND GMBH (DE) 2014-12-18 WO disclosed
US-8338613-B2 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand RIMTEC CORPORATION (JP) 2012-12-25 US disclosed
US-20110137043-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand TELENE S.A.S. (FR) 2011-06-09 US disclosed
US-20110065925-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand TELENE S.A.S. (FR) 2011-03-17 US disclosed
EP-2151446-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand Telene SAS (FR) 2010-02-10 EP disclosed
EP-2151445-A1 Process for the preparation of bidentate Schiff base ruthenium cataysts containing a saliclyldimine-type ligand Telene SAS (FR) 2010-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122376-A1 RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS OSTC, ORC3, OCIAD2 MAPT 2032/4885ALDH1A1 2520/4885KDM4E 4868/4885
US-20170145152-A1 GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION F8, COASY, FADS1 MAPT 3667/4885ALDH1A1 1858/4885KDM4E 1158/4885
US-20110137043-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand SPR, LIG4, SUCLA2 MAPT 3633/4885ALDH1A1 1371/4885KDM4E 3151/4885
US-10160828-B2 Group 8 transition metal catalysts and method for making same and process for use of same in metathesis reaction F8, COASY, FADS1 MAPT 3667/4885ALDH1A1 1858/4885KDM4E 1158/4885
US-20110065925-A1 Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand SPR, LIG4, SUCLA2 MAPT 3633/4885ALDH1A1 1371/4885KDM4E 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.